IL300023A - Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound - Google Patents

Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Info

Publication number
IL300023A
IL300023A IL300023A IL30002323A IL300023A IL 300023 A IL300023 A IL 300023A IL 300023 A IL300023 A IL 300023A IL 30002323 A IL30002323 A IL 30002323A IL 300023 A IL300023 A IL 300023A
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
total dose
day
acceptable salt
Prior art date
Application number
IL300023A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL300023A publication Critical patent/IL300023A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL300023A 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound IL300023A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063055362P 2020-07-23 2020-07-23
PCT/US2021/042877 WO2022020663A1 (en) 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Publications (1)

Publication Number Publication Date
IL300023A true IL300023A (en) 2023-03-01

Family

ID=77338898

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300023A IL300023A (en) 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Country Status (21)

Country Link
US (1) US20230338349A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185291B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535034A (cg-RX-API-DMAC7.html)
KR (1) KR20230043905A (cg-RX-API-DMAC7.html)
CN (1) CN116323604A (cg-RX-API-DMAC7.html)
AR (1) AR123031A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021312894B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000975A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186808A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000194A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000594A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000009A (cg-RX-API-DMAC7.html)
EC (1) ECSP23005057A (cg-RX-API-DMAC7.html)
ES (1) ES3039536T3 (cg-RX-API-DMAC7.html)
IL (1) IL300023A (cg-RX-API-DMAC7.html)
JO (1) JOP20230018A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000993A (cg-RX-API-DMAC7.html)
PE (1) PE20231031A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550177A1 (cg-RX-API-DMAC7.html)
TW (1) TW202220650A (cg-RX-API-DMAC7.html)
WO (1) WO2022020663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735190B (zh) * 2016-07-22 2019-11-26 深圳市大富科技股份有限公司 Usb金属管件加工设备及其上模板
TWI654978B (zh) * 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
EP3829634A1 (en) * 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy

Also Published As

Publication number Publication date
CL2023000194A1 (es) 2023-07-21
EP4185291C0 (en) 2025-07-09
CA3186808A1 (en) 2022-01-27
AU2021312894B2 (en) 2025-09-11
PE20231031A1 (es) 2023-07-10
BR112023000975A2 (pt) 2023-02-07
KR20230043905A (ko) 2023-03-31
CN116323604A (zh) 2023-06-23
ES3039536T3 (en) 2025-10-22
ECSP23005057A (es) 2023-02-28
AR123031A1 (es) 2022-10-26
MX2023000993A (es) 2023-03-01
PH12023550177A1 (en) 2024-03-18
AU2021312894A1 (en) 2023-02-23
EP4185291A1 (en) 2023-05-31
US20230338349A1 (en) 2023-10-26
JOP20230018A1 (ar) 2023-01-23
DOP2023000009A (es) 2023-02-15
CO2023000594A2 (es) 2023-01-26
WO2022020663A1 (en) 2022-01-27
EP4185291B1 (en) 2025-07-09
JP2023535034A (ja) 2023-08-15
TW202220650A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7660600B2 (ja) 慢性炎症性疾患および/または自己免疫疾患の予防または治療における使用のためのビドフルジムス(Vidofludimus)の投与レジメン
JP2022537551A5 (cg-RX-API-DMAC7.html)
FI3577124T3 (fi) Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon
JP2021512149A5 (cg-RX-API-DMAC7.html)
JP2023500032A5 (cg-RX-API-DMAC7.html)
JP2010524882A5 (cg-RX-API-DMAC7.html)
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
EP4661867A1 (en) Compositions comprising n,n-dimethyltryptamine, optionally in combination with n-acylethanolamines and uses thereof
JP2005533830A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
TWI760306B (zh) 供治療癌症之口服投予紫杉醇及P-gp抑制劑的治療性組合
JP2024528731A5 (cg-RX-API-DMAC7.html)
JP2022177119A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2023535034A5 (cg-RX-API-DMAC7.html)
CN115243686A (zh) 丁基苯酞及其衍生物的用途
IE851848L (en) Propiophenone compound against sexual dysfunction
EP2830605B1 (en) A combination medicament comprising phenylephrine and paracetamol
US20110117070A1 (en) Compositions and methods for treating headache
ES2367896T3 (es) Agente para el tratamiento del sindrome del colon irritable con predominio de diarrea.
CN115209889A (zh) 含有银杏内酯和大麻素类化合物的药物组合物及其在医药上的应用
CA2612179A1 (en) A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion
NZ258591A (en) Use of idazoxan and derivatives thereof in a medicament for treating parkinsons disease
TH2201000080A (th) การรวมกันของไอบูโพรเฟนและทรามาดอลสำหรับการบรรเทาอาการปวด